surmount-2 tirzepatide type 2 diabetes weight loss results 2023 2024 once weekly for the treatment of obesity in people with (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial Lilly released results for SURMOUNT-2,

A thorough medication review is essential, as multiple drugs can contribute to respiratory symptoms

Who is (and is not) a candidate for PT-141

Both cause appetite suppression that risks muscle loss

Semaglutide does not directly cause or increase cravings biologically

This is why many clinicians recommend: Gradual dose reductions Close monitoring of hunger and weight trends Adjustments based on real-world response Stopping suddenly is more likely to result in regain than a guided transition

Studies have already suggested that Semaglutide may improve cardiovascular health, such as blood pressure and cholesterol levels, offering additional advantages to individuals struggling with obesity-related complications